Impact of Vericiguat on Hemodynamics of Heart Failure
Impact of Vericiguat on Vascular Biology, as Well as Resting and Exertional Cardiovascular Performance Among Patients With Heart Failure With Reduced Ejection Fraction
Sponsor: University of Colorado, Denver
Listed as NCT05704478, this PHASE4 trial focuses on Heart Failure and remains ongoing. Sponsored by University of Colorado, Denver, it has been updated 7 times since 2024, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE4
Status: Not Yet Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2025 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE4
-
Dec 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE4
-
Jun 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE4
▶ Show 2 earlier versions
-
Mar 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE4
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Colorado, Denver
For direct contact, visit the study record on ClinicalTrials.gov .